Open AccessCardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
Author(s) -
Aynur Acıbuca,
Ahmet Sezer,
Mustafa Yılmaz,
Ahmet Taner Sümbül,
Şenol Demircan,
İbrahim Haldun Müderrisoğlu,
Özgür Özyılkan
Publication year - 2021
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/03000605211053755
Subject(s) - medicine , cardiotoxicity , ejection fraction , trastuzumab emtansine , coronary artery disease , cardiology , adverse effect , single center , medical record , trastuzumab , oncology , breast cancer , cancer , chemotherapy , heart failure
Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required.Methods A retrospective review of our center’s medical records was performed, including female patients aged ≥18 years with a diagnosis of metastatic breast cancer who were treated with T-DM1. Descriptive statistics were used to investigate clinical features that could increase the risk of cardiotoxicity. Cardiotoxicity was determined by comparing pre and post-T-DM1 echocardiogram results and was defined as a decrease in the left ventricular ejection fraction (LVEF) >10% to below 55%.Results Data from 41 female patients with a mean age of 52 ± 11.5 years were evaluated. A significant LVEF decrease (from 59% to 33%) was observed in one patient during T-DM1 treatment. Further investigation showed that this decrease was due to underlying coronary artery disease, and LVEF recovered to the baseline value after coronary revascularization.Conclusion T-DM1 seems to be safe in terms of cardiotoxicity. Real-life data with a larger sample size are still needed to confirm the cardiac safety of T-DM1.